[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cutter Lindbergh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100606123","cognitive-remediation-100606123",false,"NCT07171450","Cognitive Remediation","Computerized Cognitive Remediation of Postviral Neurocognitive Dysfunction in Older Adults","Inclusion Criteria:\n\n* age ≥ 60 years old\n* prior history of COVID-19 that was confirmed with viral testing (e.g., positive laboratory test or positive at-home rapid test)\n* cognitive symptoms (e.g., memory or thinking concerns) following COVID- 19 infection that have lasted for at least 12 weeks and are still present\n* clinically meaningfully subjective cognitive concerns (i.e., T-score \\\u003C 40) on the PROMIS-Cognitive Function Scale\n* objective evidence of cognitive decline\\*, as defined by performance on standardized measures of executive functioning, memory, or processing speed from the NIH Toolbox Cognition Battery that is at least 1 standard deviation below estimated premorbid cognitive functioning \\[\\*at least one third of the sample, or 25 out of 75 subjects, will be required to meet this inclusion criterion\\]\n* fluent in English language\n* off psychiatric medication or on a stable dose for at least 8 weeks\n\nExclusion Criteria:\n\n* history of neurological disorder with potential to interfere with study participation or confound results (e.g., uncontrolled seizure disorder, moderate to severe traumatic brain injury or stroke with persistent neurological deficits)\n* history of dementia and\u002For dementia range performance on the Mini- Mental State Examination (i.e., score of less than or equal to 23)\n* prior diagnosis of Mild Cognitive Impairment (MCI) or Mild Neurocognitive Disorder unrelated to the participant's history of COVID-19\n* history of severe psychiatric illness that may interfere with study participation or confound results (e.g., bipolar disorder, schizophrenia, or other psychotic disorder)\n* history of significant neurodevelopmental condition that may interfere with study participation or confound results (e.g., intellectual disability, autism spectrum disorder, or specific learning disorder with impairment in reading)\n* alcohol or other substance use disorder within the past 2 years\n* significant sensory impairments (e.g., blindness) that would interfere with the ability to complete neuropsychological measures or engage in the tablet-based intervention\n* performance that is below expectation on a test of effort and validity","ALL","60 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation (\"brain training\") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are:\n\n* Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction?\n* Will treatment effects be maintained over time, leading to better long term cognitive outcomes?\n* Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement?\n* Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction.\n\nParticipation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including:\n\n* Initial intake visit: Eligibility confirmation (\\~2-3 hours)\n* Computer activities: About 5 hours per week for \\~6 weeks (total \\~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase\n* Weekly remote check-in meetings: \\~30 minutes each during treatment\n* Blood draws: Two sessions (before and after treatment), \\~20-30 minutes each\n* Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)",[26,27,13,28,29,30],"Aging","Inflammation","Cognitive Dysfunction","Postviral Syndrome","Digital Medicine",[26,27,13,32,29,33],"Cognitive dysfunction","digital medicine","RECRUITING","2026-02-20",{"date":37,"type":38},"2026-02-24","ACTUAL",{"date":40,"type":38},"2026-01-21",{"date":42,"type":20},"2030-02-28",{"name":44,"class":45},"Cutter Lindbergh","OTHER",""]